Cardiac amyloidosis, features of diagnosis and treatment
https://doi.org/10.30629/0023-2149-2024-102-1-27-35
Abstract
Cardiac amyloidosis is considered a rare disease, but as diagnostic capabilities increase, so does the assessment of its prevalence. Cardiac amyloidosis manifests itself with symptoms of restrictive cardiomyopathy, leading to progressive heart failure. However, the underlying pathogenetic mechanisms of the disease differ. This literature review provides an overview of cardiac amyloidosis, from classification to molecular mechanisms and modern treatment options.
About the Authors
A. V. Demyanenko
Central Military Clinical Hospital named after P.V. Mandrykа of the Ministry of Defense of Russia
Russian Federation
Russian Federation
Alexey V. Demyanenko — Candidate of Medical Sciences, Deputy Head in medicine
Moscow
N. A. Varavin
Military Medical Academy named after S.M. Kirov of the Ministry of Defense of Russia
Russian Federation
Russian Federation
Nikita A. Varavin — cardiologist of the 1st Department of Therapy
Saint Petersburg
A. A. Santakov
Military Medical Academy named after S.M. Kirov of the Ministry of Defense of Russia
Russian Federation
Russian Federation
Alexander A. Santakov — student
Saint Petersburg
References
1. Myasnikov R.P., Andreyenko E.Yu., Kushunina D.V., Maksimova O.B., Beregovskaya S.A., Mershina E.А., Sinitsyn V.E., Boytsov S.A. Cardiac amyloidosis: modern aspects of diagnosis and treatment (clinical observation). Clin. Experiment. Surg. Petrovsky J. 2014;4(6):72–82. (In Russian).
2. Zhirov I.V., Safiullina A.A., Nevolina A.V., Sergienko V.B., Tereshenko S.N. Isolated atrial amyloidosis — the state of the problem. Clinical pharmacology and therapy. 2018;3:48–52. (In Russian).
3. Ansheles A .A., Nasonova S .N., Zhirov I.V., Saidova M.A., Stukalova O.V., Tereshchenko S.N., Sergienko V.B. Myocardial scintigraphy with 99m Tc-pyrophosphate in the diagnosis of cardiac amyloidosis: place in the diagnostic algorithm, features of the implementation and interpretation of the study. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(4):530–537. (In Russian). DOI: 10.26442/00403660.2022.04.201461
4. Kittleson M.M., M.S. Maurer, Ambardekar A.V., Bullock-Palmer R.P., Chang P.P., Eisen H.J., Nair A.P., Nativi-Nicolau J., Ruberg F.L. Cardiac Amyloidosis: Evolving Diagnosis and Management A Scientific Statement From the American Heart Association. Circulation. 2020;142:e7–e22. DOI: 10.1161/CIR.0000000000000792
5. Strelkova I.E. A new era in the treatment of cardiac amyloidosis: an overview of the Congress of cardiology. Lechaschi Vrach. 2021;12 (24):90–94. (In Russian). DOI: 10.51793/OS.2021.24.12.013
6. Reznik E.V., Lazarev V.A., Borisovskay S.V., Golukhov G.N. Atrial Fibrillation and Heart Failure as the Onset of AL-Amyloidosis. The Russian Archives of Internal Medicine. 2021;11(6):457–465. (In Russian). DOI: 10.20514/2226-6704-2021-11-6-457-465
7. Wang C., Chang W., Lin Y., Tzeng B., Chao T., Hung C., Wu Y., Tsai C., Lin W., Chang K., Chang H., Yu W., Wang W., Cheng C., Wang T., Hou C.J., Chen W. 2023 Expert consensus of the taiwan society of cardiology on the diagnosis and treatment of cardiac amyloidosis. Acta. Cardiol. Sin. 2023;39(4):511–543. DOI: 10.6515/ACS.202307_39(4).20230610A
8. Obi C.A., Mostertz W.C., Griffin J.M., Judge D.P. ATTR Epidemiology, genetics, and prognostic factors. Methodist DeBakey Cardiovasc. J. 2022;18(2):17–26. DOI: 10.14797/mdcvj.1066
9. Mankad A.K., Shah K.B. Transthyretin cardiac amyloidosis. Curr. Cardiol. Rep. 2017:19(10):97. DOI: 10.1007/s11886-017-0911-5
10. Ruberg F.L., Grogan M., Hanna M., Kelly J.W., Maurer M.S. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review J. Am. Coll. Cardiol.: 2019;73(22):2872–2891. DOI: 10.1016/j.jacc.2019.04.003
11. Anikonova L.I., Vorobyeva O.A., Bakulina N.V. ATTR-amyloidosis — a systemic disease involving the kidneys. Nephrologу and Dialуsis. 2022;24(3):441–456. (In Russian). DOI: 10.28996/2618-9801-2022-3-441-456
12. Reznik E.V., Nguyen T.L., Borisovskaya S.V., Brylev L.V., Zhelnin A.V., Seksyaev N.E. A clinical case of the hereditary transthyretin amyloidosis. The Russian Archives of Internal Medicine. 2021;11(3):229–240. (In Russian). DOI: 10.20514/2226-6704-2021-11-3-229-240
13. Reznik E.V., Stepanova E.A., Nguyen T.L., Sirenova I.O., Salikov A.V., Nikitin I.G. Retrospective analysis of cardiovascular involvement in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021;20(1):2496. (In Russian). DOI:10.15829/1728-8800-2021-2496
14. Reznik E.V., Nguyen T.L., Stepanova E.A., Ustyuzhanin D.V., Nikitin I.G. Cardiac amyloidosis: internist and cardiologist insight. The Russian Archives of Internal Medicine. 2020;10(6):430–457. (In Russian). DOI: 10.20514/2226-6704-2020-10-6-430-457
15. Picken M.M. The pathology of amyloidosis in classification: a review. Acta Haematol. 2020;143(4):322–334. DOI: 10.1159/000506696
16. Nikitin S.S., Bardakov S.N., Suponeva N.A., Zhirov I.V., Adyan T.A., Grishina D.A., Deev R.V. Phenotypic heterogeneity and diagnostic features of trans thyretin amyloidosis with polyneuropathy. Nervno-myshechnye bolezni (Neuromuscular Diseases). 2021;11(3):12–36. (In Russian). DOI: 10.17650/2222872120211131236
17. Adam R.D., Coriu D., Jercan A., Bădeliţă S., Popescu B.A., Damy T., Jurcuţ R. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail. 2021;8(4):2380–2396. DOI: 10.1002/ehf2.13443
18. Martinez-Naharro A., Hawkins P.N., Fontana M. Cardiac amyloidosis. Clinical Medicine. 2018;18(2):30–35. DOI: 10.7861/clinmedicine.18-2-s30
19. Marneffe N.de , Dulgheru R., Ancion A., Moonen M., Lancellotti P. Cardiac amyloidosis: a review of the literature. Acta Cardiol. 2022;77(8):683–692. DOI: 10.1080/00015385.2021.1992990
20. Adyan T.A., Polyakov A.V. Hereditary transthyretin amyloidosis. Nervno-Myshechnye Bolezni = Neuromuscular Diseases. 2019;9(4):12–25. (In Russian). DOI: 10.17650/2222-8721-2019-9-4-12-25
21. Griffin J.M., Rosenblum H., Maurer M.S. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ. Res. 2021;14;128(10):1554–1575. DOI: 10.1161/CIRCRESAHA.121.318187
22. Tung-Chen Y., Arnau M. Amyloid cardiomyopathy: a hidden heart failure cause that is often misdiagnosed. Acta Clin. Belg. 2018;73(6):460–461. DOI: 10.1080/17843286.2018.1461179
23. Muchtar E., Dispenzieri A., Magen H., Grogan M., Mauermann M., McPhail E.D., Kurtin P.J., Leung N., Buadi F.K., Dingli D., Kumar S.K., Gertz M.A. Systemic amyloidosis from A (AA) to T (ATTR): a review. J. Intern. Med. 2021;289(3):268–292. DOI: 10.1111/joim.13169
24. Vaxman I., Gertz M. When to suspect a diagnosis of amyloidosis. Acta Haematol. 2020;143(4):304–311. DOI: 10.1159/000506617
25. Opalinskaya I.V., Danilova G.V., Isaeva N.Yu., Petrova E.S., Busa laeva E.I., Vasilyeva N.P., Sergeev A.V. Primary amyloidosis with heart disease: clinical observation. Acta medica Eurasica. 2021;4:60–72. (In Russian). DOI: 10.47026/2413-4864-2021-4-60-72
26. Yamamoto H., Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 2019;6(6):1128–1139. DOI: 10.1002/ehf2.12518
27. Rameeva A.S., Rameev V.V., Moiseev S.V., Tao P.P., Kozlovskaya L.V. Amyloid heart disease: pathomorphology, diagnostic approaches and treatment options. Consilium Medicum. 2018;20(12):15–22. (In Russian). DOI: 10.26442/20751753.2018.12.000020
28. Draganova A.S., Soboleva A.V., Ertman A.E., Galanskaya T.A., Nikolaychuk E.I., Ryzhkova D.V., Polyakova E.А., Shlyakhto E.V Hereditary systemic transthyretin amyloidosis: a clinical case and an opinion on the problem. Russian Journal of Cardiology. 2019;24(6):136–142. (In Russian). DOI: 10.15829/1560-4071-2019-6-136-142
29. Cipriani A., Michieli L. De., Porcari A., Licchelli L., Sinigiani G., Tini G. et al. Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value. JACC Cardio.Oncol. 2022;4(4):458–470. DOI: 10.1016/j.jaccao.2022.08.007
30. Koike H., Okumura T., Murohara T., Katsuno M. Multidisciplinary approaches for transthyretin amyloidosis. Cardiol. Ther. 2021;10(2):289–311. DOI: 10.1007/s40119-021-00222-w
31. Akhunova C.A., Barsukovskaya T.A., Rafikov A.Yu., Sayfullina G.B. The role of echocardiography in the diagnosis of amyloidosis of the heart. Practical medicine. 2018;1(112):37–42. (In Russian). URL: http://pmarchive.ru/rol-exokardiografii-v-diagnostike-amiloidoza-serdca/
32. Akhunova S.Yu., Kirilyuk I.P., Oshchepkova I.G. Echocardiographic diagnosis of restrictive cardiomyopathies. Diary of the Kazan medical school. 2019;(23):163167. (In Russian). URL: https://www.elibrary.ru/item.asp?id=38319834
33. Siddiqi O.K., Ruberg F.L. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc. Med. 2018;28(1):10–21. DOI:10.1016/j.tcm.2017.07.004
34. Dietemann S., Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-fl utemetamol positron emission tomography. Ann. Nucl. Med. 2019;33(8):624–628. DOI: 10.1007/s12149-019-01372-7
35. Ren C., Ren J., Tian Z., Du Y., Hao Z., Zhang Z. et al. Assessment of cardiac amyloidosis with 99m Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys. 2021;8(1):3. DOI: 10.1186/s40658-020-00342-7
36. Tahara N., Lairez O., Endo J., Okada A., Ueda M., Ishii T. et al. 99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2022;9(1):251–262. DOI: 10.1002/ehf2.13693
37. Mohan J.C., Dalal J., Chopra V.K., Narasimhan C., Kerkar P., Oomman A. et al. Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: an Indian expert consensus. Indian Heart J. 2022;74(6):441–449. DOI: 10.1016/j.ihj.2022.11.006
38. Stern L.K, Patel J. Cardiac amyloidosis treatment. Methodist Debakey Cardiovasc. J. 2022;14;18(2):59-72. DOI: 10.14797/mdcvj.1050
39. Tereshchenko S.N., Zhirov I.V., Moiseeva O.M., Adasheva T.V., Ansheles A.A., Barbarash O.L. et al. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(4):584–595. (In Russian). DOI: 10.26442/00403660.2022.04.201465
40. Lysenko (Kozlovskaya) L.V., Rameev V.V., Moiseev S.V., Blagova O.V., Bogdanov E.I., Gendlin G.E. et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya = Clin. Pharmacol. Therapy. 2020;29(1):13–24 (In Russian). DOI: 10.32756/0869-5490-2020-1-13-24
41. Adams D., Koike H., Slama M., Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat. Rev. Neurol. 2019;15(7):387–404. DOI: 10.1038/s41582-019-0210-4
42. Maurer M.S. Overview of current and emerging therapies for amyloid transthyretin cardiomyopathy. Am. J. Cardiol. 2022;185:S23−S34. DOI: 10.1016/j.amjcard.2022.10.014
43. Hough A., Wearden J., Almeida K. de, Kaiser S. Review of transthyretin silencers, stabilizers, and fibril removal agents in the treatment of transthyretin cardiac amyloid. Current Cardiology Reports. 2020;22:106. DOI: 10.1007/s11886-020-01374-2
44. Gertz M.A., Mauermann M.L., Grogan M., Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: A review. Brain Behav. 2019;9(9):e01371. DOI: 10.1002/brb3.1371
45. Moiseev S.V., Rameev V.V. Tafamidis in the treatment of transthyretin amyloidosis of the heart. Clinical pharmacology and therapy. 2021;30(2):44–50. (In Russian). DOI: 10.32756/0869-5490-2021-2-44-50
46. Rapezzi C., Elliott P., Damy T., Nativi-Nicolau J., Berk J.L., Velazquez E.J. et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy JACC: Heart Failure. 2021;2:115–123. DOI: 10.1016/j.jchf.2020.09.011
47. Porcari A., Merlo M., Rapezzi C., Sinagra G. Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. Eur. J. Intern. Med. 2020;82:7–15. DOI: 10.1016/j.ejim.2020.09.025
48. Garcia-Pavia P., Siepen F.A. dem, Donal E., Lairez O., Meer P. van der, Kristen A.V. et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N. Engl. J. Med. 2023;389(3):239–250. DOI: 10.1056/NEJMoa2303765
49. Nativi-Nicolau J.N., Karam C., Khella S., Maurer M.S. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Failure Reviews. 2022;27:785–793.
50. Garcia-Pavia P., Bengel F., Brito D., Damy T., Duca F., Dorbala S. et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure. 2021;23, 895–905. DOI: 10.1002/ejhf.2198
Review
For citations:
Demyanenko A.V., Varavin N.A., Santakov A.A. Cardiac amyloidosis, features of diagnosis and treatment. Clinical Medicine (Russian Journal). 2024;102(1):27-35. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-1-27-35
Views:
508
Email this article 